Welcome.
We Are Cellsight.
Founded by the visionary Dr. Sanjiv 'Sam' Gambhir and guided by the insightful leadership of Aruna Bodapati Gambhir, CellSight Technology stands as a testament to their collective vision and commitment to advancing healthcare. Sam's groundbreaking work both shaped and revolutionized the field of molecular imaging and served as the bedrock upon which our company was established. Aruna, in her role as CEO, demonstrated unwavering dedication to realizing Sam's vision, providing clear direction, and cultivating a dynamic network within the industry. Together, their contributions have not only shaped the core values of the company but have also set a trajectory that brings CellSight one step closer to precision health.
The indelible legacy forged by Sam and Aruna, defined by their resilience, unyielding optimism, and compassionate spirit, remains the driving impetus behind CellSight’s relentless pursuit of progressive solutions, and our steadfast commitment to improving patient outcomes.
Sam Quezada, MBA
Mr. Quezada co-founded CellSight Technologies with Drs. Sanjiv Gambhir and Shahriar Yaghoubi to commercialize molecular imaging technologies developed in Dr. Gambhir’s lab at Stanford University. With years of experience in startups and high-growth companies, he has recently managed IP and corporate relations at MIPS (Molecular Imaging Program at Stanford).
His executive roles have encompassed operations, marketing, business development, and strategic planning. At Cirrus Logic, his focus on customer needs and translating those needs into product delivery led to multi-million-dollar engagements with several clients. Mr. Quezada holds a BS in Electrical Engineering and an MBA from Stanford University.
Jelena Levi, PhD
Dr. Levi holds a BS in Chemistry from the University of Belgrade, Yugoslavia, and a PhD in Organic Chemistry from the Graduate Center, CUNY, earned under the mentorship of Dr. Klaus Grohmann. She launched her career in molecular imaging in the lab of Dr. Sanjiv Sam Gambhir at Stanford University. Dr. Levi's research focuses on the development of targeted imaging agents for cancer detection, immune cell visualization, and treatment monitoring.
Over the years, she has designed, developed, and evaluated a wide range of imaging agents, including small molecules, peptides, engineered proteins, and nanoparticles, for use in multiple imaging modalities such as PET, optical, and photoacoustic imaging.
Our Network
In our pursuit of innovation and excellence we are committed to fostering collaborative partnerships that drive the boundaries of healthcare forward. We invite collaborators and stakeholders passionate about advancing precision medicine to join us in our mission to revolutionize patient care and therapeutic outcomes.